FIELD: biotechnology.
SUBSTANCE: invention relates to a chimeric antigen receptor (CAR) with lower tonic signaling when expressed in immune cells compared to immune cells expressing CAR without the intracellular co-stimulatory signaling domain of TNFR2, as well as a nucleic acid encoding it. An immune cell expressing the above CAR, as well as a population containing it, are also disclosed.
EFFECT: invention is effective for treating a disease or disorder in a human subject, where the disease or disorder is selected from the group consisting of an inflammatory disease, an autoimmune disease, an allergic disease, a post-organ transplant condition, cancer and an infectious disease.
17 cl, 15 dwg, 13 tbl, 5 ex
| Title | Year | Author | Number |
|---|---|---|---|
| TREATMENT OF MALIGNANT NEOPLASM USING HUMANIZED CHIMERIC ANTIGEN RECEPTOR AGAINST BCMA | 2015 |
|
RU2751660C2 |
| ISOLATED ALTERNATIVE INTRACELLULAR SIGNALLING DOMAIN OF CHIMERIC ANTIGEN RECEPTOR AND CHIMERIC ANTIGEN RECEPTOR INCLUDING IT | 2019 |
|
RU2742000C2 |
| CD19-SPECIFIC CHIMERIC ANTIGEN RECEPTOR AND USE THEREOF | 2014 |
|
RU2727447C2 |
| RITUXIMAB-RESISTANT CHIMERIC ANTIGEN RECEPTORS AND WAYS OF USE THEREOF | 2020 |
|
RU2816370C2 |
| CHIMERIC ANTIGEN RECEPTOR | 2016 |
|
RU2752880C2 |
| COMBINATION OF CELL THERAPY AND IMMUNOMODULATOR COMPOUND | 2018 |
|
RU2777911C2 |
| ANTI-CLL1-SPECIFIC SINGLE-CHAIN CHIMERIC ANTIGENIC RECEPTORS (SCCAR) FOR CANCER IMMUNOTHERAPY | 2016 |
|
RU2731543C2 |
| CD123-SPECIFIC CHIMERIC ANTIGENIC RECEPTORS FOR CANCER IMMUNOTHERAPY | 2015 |
|
RU2727290C2 |
| CHIMERIC ANTIGENIC (CAR) RECEPTOR AGAINST CD123 FOR USE IN TREATING MALIGNANT TUMORS | 2015 |
|
RU2724999C2 |
| CELL | 2014 |
|
RU2717984C2 |
